Navigation Links
InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
Date:9/4/2007

- Phase 1b trial expected to begin in September -

BRISBANE, Calif., Sept. 4 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that the amended Clinical Trial Authorization (CTA) related to the Phase 1b clinical trial of ITMN-191 (Roche-R7227) has been approved by the appropriate European regulatory authorities. InterMune also has received approval from the Ethics Committee of the institutions that will conduct the Phase 1b study. ITMN-191 is an orally available hepatitis C virus (HCV) protease inhibitor in development by InterMune and its partner, Roche.

InterMune expects that the Phase 1b multiple ascending dose (MAD) study will begin this month and expects to announce initial top-line viral kinetic and safety results from the first three dose cohorts of the MAD study in the first quarter of 2008.

Dan Welch, President and Chief Executive Officer of InterMune, said, "InterMune and Roche are pleased to announce that we have successfully secured the required regulatory approvals that enable us to initiate our very important Phase 1b multiple ascending dose study. By amending the Phase 1b protocol, we believe we have enhanced our ability to deliver the most robust Phase 1b results possible which we expect will place us in a stronger position to begin our Phase 2 trials."

In early May, InterMune announced that it would amend the CTA to take into consideration new information on competitive protease inhibitors, in-vitro and preclinical data on ITMN-191 and pharmacokinetic observations from a Phase 1a study that was completed in May of 2007. In that study, a higher than anticipated exposure of ITMN-191 in plasma was observed in subjects dosed with food, suggesting tha
'/>"/>

SOURCE InterMune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. InterMune Presents Research on ITMN-191 in Hepatitis C at EASL Annual Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  Uroplasty, Inc. (NASDAQ: UPI ... and markets innovative proprietary products to treat voiding ... 2015 first quarter ended June 30, 2014.  ... Neuromodulation System grew 19% to $4.1 million, as ... of the prior year.  Total revenue for the ...
(Date:7/24/2014)... 24, 2014 Omnicell, Inc. (NASDAQ: ... and supply management solutions and analytics software for ... 31, to discuss the Company,s Second Quarter 2014 ... 2014 earnings conference call and webcastWhen: , ... Lipps, chairman, president and chief executive officer ...
(Date:7/24/2014)... 24, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... of fiscal year 2014 financial results after the market ... call will follow on the same day at 4:30 ... be hosted by Dan Myers , President and ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2Alimera Sciences To Release Second Quarter 2014 Results 2
... A new approach to unblocking heart arteries minimally invasively ... and less risk overall, particularly for obese patients, according ... Symposium on Endovascular Therapy (ISET). Every year, about one ... open their blocked arteries. New data suggests that beginning ...
... Excalibur, the international,investment house specialising in medical ... to deliver pioneering stem cell treatments if it ... , Professor Sir Christopher ... that ReNeuron plc has received approval from the ...
Cached Medicine Technology:Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries 2UK Must Maintain its Momentum in Stem Cell Expertise 2
(Date:7/24/2014)... Kathleen Doheny HealthDay Reporter ... of obese children often don,t view their kids as unhealthy ... according to a new study. The children of the ... clinic at the Hasbro Children,s Hospital in Providence, R.I. ... good," said study researcher Dr. Kyung Rhee, now an assistant ...
(Date:7/24/2014)... treatment of overweight and obese preschoolers works better when ... only the child is targeted, according to research published ... the University at Buffalo and Women and Children,s Hospital ... or obese and had one parent who participated in ... to body mass index (BMI) measurements, calculated based on ...
(Date:7/24/2014)... like a medical device or surgical implant is put ... to Northwestern University,s Guillermo Ameer, most of the time, ... function. , "You will always get an inflammatory response ... in Northwestern,s McCormick School of Engineering and Applied Science ... Medicine. "A problem with commonly used plastic materials, in ...
(Date:7/24/2014)... Horizon BCBSNJ’s second annual “Back to ... a rent-free week in a beautiful Lavallette shore house, ... miss your chance to win a week’s vacation at ... New Jersey residents, 25 or older.* Residents can enter ... . , “A family vacation at the Jersey ...
(Date:7/24/2014)... IA (PRWEB) July 24, 2014 Members of ... Michael Wolnerman, RPh, CCIM, Senior Associate of Sales at OutcomesMTM, ... Governor appointed him to the Board and that his peers ... “I want to provide the best I can for the ... I am uniquely positioned to provide a special insight to ...
Breaking Medicine News(10 mins):Health News:Parents of Obese Kids Often View Them as Healthy 2Health News:Parents of Obese Kids Often View Them as Healthy 3Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Antioxidant biomaterial promotes healing 2Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2
... the numbers of heart transplants are on the decline. This ... properly//. Hence the doctors at the Papworth Hospital in Cambridge ... for five hours after it was removed from the donor. ... transplant was Michael Burt, 58, a builder from Burnham Market, ...
... US –based research has given hopes that researchers will be ... in the ears of humans challenged by deafness//. ,These tiny ... is then translated by the brain into sound. Once ... in permanent hearing loss. , ,Approximately, one out of every ...
... studies by Canadian researchers show that the male ... that are not recognized and understood// many health ... researchers found that though both male and female ... anxieties and fears about their encounters with health ...
... standards officers have issued a warning to the public that ... prescription drugs through the Internet//. , , Drugs such as ... have often turned out to be fakes or ... partaking of drugs without a prescription can turn ...
... the 23rd June recalled almost around 20,000 chocolate bars ... fears// that those bars may contain traces of salmonella. ... that there were minute traces of salmonella, which though ... the scientific standards for any hazards. The spokesperson had ...
... ahead of Sunday's game, after research has shown that the ... football matches. The game with Ecuador is the first knockout match ... BUPA said: "When people's emotions run high stress levels can shoot ... that history does not repeat itself”. "If England gets ...
Cached Medicine News:Health News:Latest In the Heart Transplant Field 2Health News:Sexually Abused Males Found Struggling In heir relations with Healthcare Providers 2
... 5500s electronic architecture incorporates advanced circuit designs ... it HI VUE an engineering philosophy ... to individual specifications while, at the same ... system. The end result is extraordinary performance ...
... endoscope with a built-in electronic scanning system. ... image under echo. It is also equipped ... observation. The EG-3630UR has achieved the highest ... well as exceptional ultrasound imaging capability. The ...
... is an affordable solution for low volume ... test menu includes a variety of clotting ... The ACL 1000 also offers bar code ... lab. Plus, it's backed by superior technology ...
... CX4-S system consolidates DATs, TDMs ... one workstation, targeted to the ... samples per day. Like all ... CX4-S is easy to use, ...
Medicine Products: